Real-world polypharmacy and healthcare resource utilization after early-line treatment with cannabidiol for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex

Patients with treatment-resistant epilepsy initiating cannabidiol (CBD) therapy often remain on multiple antiseizure medications, but the real-world impact of CBD on polypharmacy burden and healthcare resource utilization had not been characterized beyond clinical trials.

Target RWE researchers analyzed real-world data from early-line CBD-treated epilepsy patients to characterize changes in ASM polypharmacy and healthcare resource utilization following CBD initiation, funded by Jazz Pharmaceuticals.

Demonstrating real-world reductions in ASM polypharmacy after CBD initiation provides Jazz Pharmaceuticals with post-market effectiveness evidence supporting label messaging and payer arguments for CBD as a polypharmacy-reducing add-on therapy.

CBD post-market effectiveness evidence for ASM polypharmacy reduction in epilepsy for Jazz Pharmaceuticals, Real-world HCRU evidence supporting cannabidiol label and payer strategy in treatment-resistant epilepsy